Cargando…

Use of Pegylated Interferon Alpha-2a in Cutaneous T-cell Lymphoma: A Retrospective Case Collection

Mycosis fungoides and Sézary syndrome are rare and largely incurable types of cutaneous T-cell lymphoma with limited therapeutic options. In 1984 Bunn et al. reported that interferon alpha is an efficient monotherapy in cutaneous T-cell lymphoma and 14 years later it was shown in a prospective, rand...

Descripción completa

Detalles Bibliográficos
Autores principales:	GOSMANN, Janika, STADLER, Rudolf, QUINT, Koen D., GUTZMER, Ralf, VERMEER, Maarten H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medical Journals Sweden, on behalf of the Society for Publication of Acta Dermato-Venereologica 2023
Materias:	Original Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622159/ https://www.ncbi.nlm.nih.gov/pubmed/37902466 http://dx.doi.org/10.2340/actadv.v103.10306

Ejemplares similares

Non-pegylated and Pegylated Interferon Alpha-2a in Cutaneous T-cell Lymphoma and the Risk of Severe Ocular Side-effects
por: ALBRECHT, Jana D., et al.
Publicado: (2022)

Itch in patients with cutaneous T-cell lymphoma as a quality of life indicator
por: Ottevanger, Rosanne, et al.
Publicado: (2022)

Generalized Molluscum Contagiosum Successfully Treated with Interferon-Alpha in a Patient with Folliculotropic Mycosis Fungoides
por: Melchers, Rutger C., et al.
Publicado: (2019)

Reply to Correspondence to “Itch in patients with cutaneous T-cell lymphoma as a quality of life indicator”
por: Ottevanger, Rosanne, et al.
Publicado: (2022)

A rare case of cutaneous Epstein-Barr virus–negative intravascular cytotoxic T-cell lymphoma
por: Melchers, Rutger C., et al.
Publicado: (2019)

Quality of Life in Cutaneous T-cell Lymphoma Patients Receiving Mogamulizumab: Important Factors to Consider
por: Ottevanger, Rosanne, et al.
Publicado: (2022)

Corresponding anaplastic lymphoma kinase–tropomyosin 3 (ALK-TPM3) fusion in a patient with a primary cutaneous anaplastic large-cell lymphoma and a Spitz nevus
por: Melchers, Rutger C., et al.
Publicado: (2019)

Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B
por: Zhang, Wenhong, et al.
Publicado: (2018)

Pegylated Interferon Alpha for Chronic Hepatitis B Virus Infection
por: Vasconcelos, Joana, et al.
Publicado: (2022)

Epidemiology of cutaneous lymphoma
por: Vermeer, M.
Publicado: (2021)

Unveiling the hidden struggles: Exploring the profound impact of advanced stage cutaneous T‐cell lymphoma on quality of life
por: Ottevanger, Rosanne, et al.
Publicado: (2023)

Whole-genome profiling of primary cutaneous anaplastic large cell lymphoma
por: Torres, Armando N. Bastidas, et al.
Publicado: (2021)

Pegylated interferon-alpha-2a for the treatment of ocular surface squamous neoplasia
por: Nuruddin, Murtuza, et al.
Publicado: (2022)

Cutaneous side effects of combination therapy of pegylated interferon 2α and ribavirin
por: Raducan, Anca, et al.
Publicado: (2014)

Serum and cutaneous transcriptional expression levels of IL31 are minimal in cutaneous T cell lymphoma variants
por: van Santen, S., et al.
Publicado: (2021)

Pegylated-Interferon Alpha Therapy for Treatment-Experienced Chronic Hepatitis B Patients
por: Yeh, Ming-Lun, et al.
Publicado: (2015)

Nanomedicines in the treatment of chronic hepatitis C – focus on pegylated interferon alpha-2a
por: Thomas, Thea, et al.
Publicado: (2007)

Pegylated liposomal-encapsulated doxorubicin in cutaneous composite lymphoma: A case report
por: Wollina, Uwe, et al.
Publicado: (2016)

A Case of Chronic Neutrophilic Leukemia Successfully Treated with Pegylated Interferon Alpha-2a
por: Yassin, Mohamed A, et al.
Publicado: (2015)

Pegylated interferon alpha-2a (40 kDa) in the treatment of chronic hepatitis B
por: Lai, Lawrence, et al.
Publicado: (2006)

Acute pancreatitis associated with pegylated interferon-alpha-2a therapy in chronic hepatitis C
por: Choi, Jong Wook, et al.
Publicado: (2016)

Cutaneous Sarcoidosis: An Uncommon Side Effect of Pegylated Interferon and Ribavirin Use for Chronic Hepatitis C
por: Martins, Elson Vidal, et al.
Publicado: (2009)

Nanomedicines in the treatment of patients with hepatitis C co-infected with HIV – focus on pegylated interferon-alpha
por: Zoller, Heinz, et al.
Publicado: (2006)

Acute pericarditis due to pegylated interferon alpha therapy for chronic HCV hepatitis - Case report
por: Popescu, Cristina, et al.
Publicado: (2011)

Thyroid disturbances in children treated with combined pegylated interferon-alpha and ribavirin for chronic hepatitis C
por: Rashed, Yasser K., et al.
Publicado: (2020)

Pegylated Interferon Alpha-2b in Patients With Polycythemia Vera and Essential Thrombocythemia in the Real World
por: Sun, Yingxin, et al.
Publicado: (2021)

Successful Treatment of Provisional Cutaneous Mastocytosis with Interferon Alpha
por: Rosario, Andrea, et al.
Publicado: (2016)

Pegylated interferon alpha-2a monotherapy in a peritoneal dialysis patient with chronic hepatitis C
por: Mimura, Imari, et al.
Publicado: (2008)

Differential expression of interferon-induced microRNAs in patients with chronic hepatitis C virus infection treated with pegylated interferon alpha
por: Scagnolari, Carolina, et al.
Publicado: (2010)

Total skin electron beam therapy for cutaneous T-cell lymphomas in the Netherlands: A retrospective analysis of treatment outcomes and selection for high or low dose schedule
por: Smits, K., et al.
Publicado: (2022)

A detailed characterization of peripheral blood lymphocytes in patients with myeloproliferative disease treated with pegylated-interferon alpha
por: Kovacsovics-Bankowski, Magdalena, et al.
Publicado: (2015)

Comparison of adefovir dipivoxil and pegylated interferon alpha-2a treatment in chronic hepatitis B patients
por: Korkmaz, Pinar, et al.
Publicado: (2014)

Ischaemic colitis during pegylated interferon-alpha monotherapy for chronic hepatitis B: A case report
por: Liu, Yu, et al.
Publicado: (2022)

Large Intestine Histopathology of Pegylated-Interferon-Alpha Plus Ribavirin Treated Chronic Hepatitis C Patients
por: Pantazis, Konstantinos D., et al.
Publicado: (2008)

‘Double-hit’ pegylated interferon-alpha successfully treats Hepatitis B and Hepatitis D co-infection
por: Bhuva, Meha, et al.
Publicado: (2020)

Analysis of clinical characteristics of thyroid disorders in patients with chronic hepatitis B treated with pegylated-interferon alpha
por: Liu, Yisi, et al.
Publicado: (2023)

The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C
por: Keshvari, Maryam, et al.
Publicado: (2016)

Interferon-lambda 3 and 4 Polymorphisms Increase Sustained Virological Responses and Regulate Innate Immunity in Antiviral Therapy With Pegylated Interferon-Alpha
por: da Silva, Andréa Marques Vieira, et al.
Publicado: (2021)

Hepatitis C Virus Clearance after Discontinuation of Pegylated Interferon Alpha-2a Monotherapy in a Child
por: Endo, Takeshi, et al.
Publicado: (2012)

Flow cytometry for the assessment of blood tumour burden in cutaneous T‐cell lymphoma: towards a standardized approach
por: Vermeer, Maarten H., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a8j1qp2mbghm6elbjrnbtrs8kc